Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK first quarter profit dips to £1.49 billion but beat analyst forecasts
03:21am, Wednesday, 26'th Apr 2023
GSK PLC UK:GSK on Wednesday reported net profit and sales that beat expectations but declined on-year, and backed its guidance for the full year 2023.
GSK shares open higher as Q1 sales and profits beat expectations
03:13am, Wednesday, 26'th Apr 2023
Shares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher after its first-quarter revenue and profits beat expectations with the outperformance driven by the success of its Shingrix shingles vaccine. It als
GSK and Standard Chartered earnings on Wednesday, plus US tech giants report
11:00am, Tuesday, 25'th Apr 2023
Standard Chartered PLC (LSE:STAN) will be the first of the FTSE 100 banks to report first-quarter results, having disappointed with earnings last time, but got a modest round of applause for better-t
GSK minds the gap as AstraZeneca streaks ahead
08:37am, Tuesday, 25'th Apr 2023
GSK's first quarter should see the UK pharma in decent shape operationally says analysts though the ongoing legal battle over Zantac compensation will remain the main influence on the share price unti
AstraZeneca results arrive with focus on drug trials, while GSK still faces Zantac overhang
01:23pm, Friday, 21'st Apr 2023
The FTSE 100's biggest company reports next week, AstraZeneca PLC (LSE:AZN) stepping up with a first-quarter trading update on Thursday, preceded by a day by its former close rival GSK PLC (LSE:GSK, N
GSK, Merck deals show appetite is ripe for biopharmaceutical M&A
04:56pm, Tuesday, 18'th Apr 2023
Biopharmaceutical companies are getting stock price lifts this week after two big deals in the space signal that M&A appetite is ripe. On Tuesday, GSK PLC (LSE:GSK, NYSE:GSK) revealed it has paid ar
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
09:56am, Tuesday, 18'th Apr 2023
GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged.
Bellus Health's stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss
08:31am, Tuesday, 18'th Apr 2023
Here are some of the biggest movers on Tuesday:
GSK Inks $2 Billion For Cough Medicine Biotech To Bolster Drug Pipeline
05:22am, Tuesday, 18'th Apr 2023
GSK said Bellus' experimental cough medicine could help treat millions of people with untreatable chronic coughs and had “significant sales potential” if approved.
GSK pays £1.6bn for Canada's Bellus Health
02:48am, Tuesday, 18'th Apr 2023
GSK PLC (LSE:GSK, NYSE:GSK) has paid around £1.6bn for Bellus Health (TSX:BLU) Inc, a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments. The pharmaceutica
GSK to acquire U.S.-based BELLUS Health for $14.75 per share
02:33am, Tuesday, 18'th Apr 2023
GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $14.75 a share in cash, representing a total equity
GSK reports positive phase 3 data for UTI oral antibiotic
02:58am, Monday, 17'th Apr 2023
GSK PLC GSK, -0.49% on Monday reported positive data from its phase 3 studies for gepotidacin, its late-stage oral antibiotic for uncomplicated urinary-tract infections in female adults and teenagers.
GSK growth outlook being overlooked due to Zantac concerns
07:56am, Wednesday, 12'th Apr 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s growth outlook is being overlooked and the worst-case scenario for Zantac continues to be reflected in the share price. That's the view of Shore Capital which reiterated
GSK: Will vaccines do the trick? This leading bank has its say
12:19pm, Monday, 03'rd Apr 2023
Deutsche Bank repeated its ‘buy' advice and 1,700p price target for shares in GSK PLC (LSE:GSK, NYSE:GSK) in an update which assessed the news flow around its Hepatitis B research. Put simply, the l
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
08:48am, Friday, 31'st Mar 2023
Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out. The post J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out appear
